The biopharmaceutical industry has been significantly transformed by the increasing reliance on monoclonal antibodies (MAbs) for therapeutic applications. As the demand for these biopharmaceuticals grows, so does the need for more efficient purification methods. Traditionally, antibody purification has relied on a three-column platform that includes Protein A affinity chromatography, followed by anion exchange (AEX) and cation exchange (CEX) chromatography. However, recent innovations in using membrane adsorbers present a promising alternative that could streamline the manufacturing process while enhancing product quality.
In the conventional approach, the Protein A affinity column captures the antibodies from the feed stream, effectively isolating them from contaminants. This is followed by AEX chromatography in flow-through mode, which targets negatively charged impurities such as host cell proteins (HCP), endotoxins, and residual DNA. Finally, CEX or hydrophobic interaction chromatography (HIC) is employed to eliminate positively charged impurities. While this method has served the industry well, it faces limitations as production scales increase. The bottleneck created during downstream processing can hinder overall efficiency and escalate costs.
Membrane adsorbers offer a compelling solution to these challenges. These devices are designed with synthetic microporous or macroporous membranes that are functionalized similarly to traditional resins. By stacking multiple layers of these membranes in a compact cartridge, they achieve a significantly smaller footprint compared to conventional columns. This design not only minimizes buffer consumption but also allows for higher flow rates, enhancing the speed of the purification process.
The efficacy of membrane adsorbers stems from their unique mechanism of solute transport, which predominantly relies on convection rather than pore diffusion. Consequently, these adsorbers can process large volumes of antibodies in a fraction of the time required by traditional methods. For instance, in applications like flow-through AEX, membrane adsorbers can operate at flow rates exceeding 600 cm/h, achieving substantial reductions in processing times.
A recent study conducted by Philogen demonstrated the successful integration of membrane adsorbers into antibody purification processes. After an initial capture step using Protein A affinity chromatography, the feed stream was directed to a Sartobind Q AEX membrane adsorber, followed by a Sartobind S CEX adsorber. This dual system allowed for the simultaneous removal of various contaminants, achieving up to 90% recovery and 99.9% purity for the MAb Teleukin, currently in clinical trials.
The polishing step involved two Sartobind ion exchange adsorbers arranged in series. The AEX adsorber captured negatively charged impurities, while the CEX adsorber removed positively charged contaminants. This integrated approach streamlined the process, significantly enhancing both efficiency and product quality. The results indicated that this method could be reliably scaled up, allowing for the processing of large batches with high yields.
In addition to efficiency, membrane adsorbers also present the advantage of linear scalability. Parameters such as frontal surface area, flow rate, and static binding capacity can be adjusted without compromising performance. This makes it easier for manufacturers to adapt their processes as production demands change, a critical factor in the rapidly evolving biopharmaceutical landscape.
Despite the advantages of membrane adsorbers, traditional packed-bed chromatography still holds a crucial role, particularly in the capture of smaller molecules and when specific gradient elutions are necessary. However, for larger molecules, which encompass most contaminants in antibody production, membrane technology provides a faster and more cost-effective alternative.
The final steps of the purification process typically include a thorough nanofiltration operation designed to remove any residual viruses. Using a high-capacity filter, manufacturers can achieve impressive recovery rates while ensuring compliance with stringent regulatory standards. This final purification stage is vital for ensuring the safety and efficacy of biopharmaceutical products.
As the biopharmaceutical industry continues to evolve, the adoption of innovative technologies like membrane adsorbers is likely to become more widespread. The ability to simplify purification processes while maintaining high product quality positions these devices as a favorable alternative in the competitive landscape of MAb production.
Key Takeaways:
- Membrane adsorbers offer a compact and efficient alternative to traditional chromatography methods, enhancing purification speed and reducing costs.
-
The integrated use of membrane adsorbers can achieve high recovery rates and purity levels for monoclonal antibodies.
-
Membrane technology allows for linear scalability, making it adaptable to varying production demands.
-
While membrane adsorbers are advantageous for larger molecules, traditional chromatography remains essential for capturing smaller impurities.
-
The final purification stage often includes nanofiltration to ensure virus safety and regulatory compliance.
With ongoing advancements in purification technologies, the future of antibody manufacturing looks promising, paving the way for more efficient and effective biopharmaceutical production.
Read more about it here → biopharminternational.com
Read more on biopharminternational.com